Because curcumin and POH have little or no toxicity (34, 38) and may not affect Sp1 expression or subsequently alter constitutive CD59 expression, these findings strongly suggest that curcumin and POH are ideal adjuvants to restore rituximab sensitivity by suppressing the over-expression of CD59 on rituximab-resistant lymphoma cells. This evidence concerns the gene SP1 and lymphoma.